TDM in Oncology
-
Last Updated: Thursday, 03 September 2020 10:25
 |
Chair
Gareth Veal Newcastle upon Tyne, UK
|
Contact Us Scientific Committees TDM in Oncology Committee
|
Background & Purpose of the Committee
- Creating and promoting awareness of the need for TDM in cancer therapy,
- Stimulating studies which demonstratethe utility in improving patient outcomes,
- Education of the IATDMCT members on advances and opportunities in the area,
- Education of medical oncologists and regulatory authorities of the importance of TDM in oncology,
- Development of consensus guidelines for implementationncology.
Scope of the Oncology Committee is:
- TDM for cancer treatment in hematology and oncology,
- Chemotherapy, molecular targeting therapy, hormonal therapy and immunotherapy,
- Topics relating to drug concentrations in blood, pharmacogenomics and other biomarkers for the benefit of precision medicine.
Activities Planned/Committee Initiatives Currently in Progress
- Consensus guideline document for TDM of busulfan
- Consensus guideline document for TDM of imatinib
- Consensus guideline document for TDM of paclitaxel
- Support the 2020 meetings with workshops and symposia
Past Years' Activities Held/Committee Initiatives
- Consensus guideline document for TDM of 5-Fluorourac.
- Support the 2019 meetings with workshops and symposia